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Abstľact: Using a combination of three complementary screening tech-
niques we investigated 186 Slovenian families with 2 or more cases of
breast/ovarian cancer and found a cancer predisposing mutation in 57 fami-
lies (30%). when considering families with more than 4 breast cancer cases or
with at least one ovarian tumouĹ the mutation recovery rate rises to 50%. The
BRCA|/2 mutations found in the Slovene population are distributed over the
whole length of both genes but because of the high incidence of a few of
these mutations, a restricted molecular screening covering only four DNA
fragments can identify two third of them. A limited screen can thus be offered
to persons that do not meet the strict intake criteria. Finally, since the genetic
cancer predisposing factor seems to be missed in a significant Íraction of the
families (50% oÍ Slovenian families), efforts are made worldwide (1) to amelio-
rate the screening efficiency of the BRCA1/2 genes and (2) to identiÍy other
breast cancer predisposing genes.
Breast cancer is a very common disease affecting some 10% of western
Women. Although the disease occurs mostly in the sporadic form, Íamilial
clustering is observed in about 10o/o oÍ the cases. Linkage analyses per-
formed in the early nineties, aimed to identify the chromosomal regions
involved in this genetic cancer predisposition, indicated that 2 loci located at
17 q21 and 1 3q 1 2 must be responsible Íor the disease in 80%o of high risk fam-
ilies. Two breast cancer predisposing genes, BRCAI and BRCA2, were iden-
tified respectively in 1994 and '1995. From that moment on, molecular analy-
ses of the BRCA1 and BRCA2 genes became possible, and knowing the dis-
ease causing mutation in a pańicular family became a very impońant tool for
the counselling of this familY.
BRCAI and BRCA2 are very large genes organized in respectively 23 and 27
exons. Moreover, it became rapidly clear that the identified mutations are dis-
tributed over the whole length of the coding sequences. Mutation screening
thus appeäred to be a time and money consuming enterprise and the need for
selective intake criteria was obvious. Today, mutation analysis of the full cod-
ing sequence of BRCA1 and BRCA2 can be offered by the maiority of the
genetic diagnostic laboratories, although the used screening techniques may
vary somehow.
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ln our laboratory (VUB Brussels) we use a combination of 3 different tech-
niques to screen the BRCAI/2 genes. The analyses are performed on genom-
ic DNA prepared from blood samples of cancer affected persons.
The Protein Truncation Test (PTf) is applied for the analysis of the few large
exons. Genomic stretches of DNA obtained by pcR are used lN VlrRo to
generate the corresponding protein sequences. These proteins are subse-
quently analysed on a polyacrylamide gel. A control person (with wild type
DNA sequences) will generate a protein with a specific length. However, a
patient carrying a nonsense or frameshift mutation in one allele will in addĺtion
show a second band on a proteln gel, the smallest one corresponding to the
mutant form. The advantage of the PTT technique is that it is less time con-
suming, can be applied on relatively large pCR fragments (and thus conve-
nient for the analysis of large exons), and all identified mutations can be clas-
sified as cancer predisposing since they generate truncated proteins.
Disadvantage is that we miss the missense mutations. However, this is not
seen as very disturbing since only very few missense mutations can be clas-
sified as cancer predisposing at this moment. The majorĺty of them are benign
polymorphisms or are reported as "unclassified variants" and thus non-infor-
mative for clinical purposes.
The Denaturing Gradient Gel Electrophoresis (DGGE) is used to analyse all the
remaining protein encoding small exons (57 in total). pcR fragments are first
generated Íor each of these exons. The fragments are then heat denatured
and renatured. when performed on a control sample (both alleles being iden-
tical and wild type), this will generate only one type of double stranded DNA
molecules. However, heterozygous mutation carriers will generate 4 different
types of DNA duplexes: 2 homoduplexes and 2 heteroduplexes. These 4
duplex molecules have each a specific temperature at which the DNA strands
will separate. When loaded and run on a polyacrylamide gel in which an
increasing denaturing gradient has been build up, fragments will migrate until
they reach a position in the gel where the DNA strands will separate. since a
40 base pair long sequence with high GC content (the GC clamp) was added
artificially at one end of the PCR Íragment (via a modified PcR primer), the
DNA strands will not totally separate but remain attached at one extremity.
This will result in the generation of a conformation that prevents further migra-
tion through the gel. Heterozygous mutant samples will thus show 4 bands
after gel migration, control samples only one. The DGGE method works well
on 200-300 base pair long DNA fragments, and is thus adequate for the anal-
ysis of small exons. ln contrast to the PTT method, DGGE picks up the mis-
sense mutations, but since most oÍ them are benign polymorphisms, many
"Íalse positives'' will be identified.
The two techniques presented here above are able to detect mutations affect-
ing only one or a few nucleotides (missense, nonsense, inserlions or deletions
a few nucleotides long). However, more recently several groups reported dele-
tions or duplications involving one or several consecutive exons. These muta-
tions are probably generated when a recombination occurs between mis-
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aligned sequences. Since the intronic sequences of BRCAI are very rich in
repetitive elements (e.9. Alu repeat), misalignments and subsequent recombi-
nations can be expected and are indeed observed. Such mutations are almost
not encountered in the BRCA2 gene. ln the past, mutations involving large
stretches of DNA could be identified using time consuming techniques such
as Southern blots, but recently a new approach was developed (MLPA) that is
currently used for the routine screen of BRCA1 .
We applied the BRCA genetic analysis on 186 Slovene families, and a cancer
predisposing mutation was detected in 57 of them. Although the mutations
were dispersed over the whole length of the BRCA'I and BRCA2 coding
sequences, 5 distinct mutations occurred very frequently in the population.
This clustering has very important consequences for the genetic screen.
lndeed, since the analysis of only 4 PCR fragments led to the identiÍication of
the cancer predisposing mutations in 39 of the 57 BRCA1/2 positive Slovene
families (68%), the genetic screen will always be initiated at these 4 particular
DNA regions. Moreover, persons or families who do not strictly meet the
including criteria for the genetic screen can be submitted to a restricted anal-
ysis (e.g. women with bilateral breast cancer or women who developed breast
and ovarian cancer). A population based study can eventually be perÍormed
on the Slovene population to estimate the frequency oÍ BRCA mutations in
isolated breast cancer patients (male or female).
one of the mutations Írequently occurring in the Slovene population (lVS16-
2A>G) was found exclusively in Slovenia or at the Slovenian border in ltaly,
while 2 other recurrent mutations (1806C>T and 5382insC) have been
encountered in many other countries. Very unexpected is the frequent occur-
rence of cancer predisposing missense mutations affecting one of the con-
served residues that define the RlNG Íinger motif located near the protein NH,
terminus (encoded by exon3 and exons of BRCA1).
ln breast cancer only families (no cases of ovarian cancer) with 5 or more can-
cer patients we could identify aBRCA1/2 mutation in about 5o%o oÍ the fami-
lies. When less breast cancer cases occurred in the Íamily' the mutation
recovery rate also decreases (e.9. only 12%oin families with 2 breast cancer
cases). A possible explanation Íor this observation is the occurrence of sever-
al sporadic breast cancers within a same family. A similar decrease of the
recovery rate is not observed however in families with breast and ovarian can-
cer. ln those families the mutation recovery rate is 50% independently of the
number of cancer affected relatives, confirming the hereditary nature of the
disease even in families with a restricted number oÍ cancer patients. Since the
highest observed mutation recovery rate in Slovene families is 50% even in
those families with a high number of affected relatives (and with ovarian can-
cer), we may suppose that a whole set of cancer predisposing mutations
escape to our attention. At least part oÍ them might be located in BRCA1
and/or BRCA2 but are not detectable with the currently used screening tech-
niques (e.g. mutations located in the promoter region or within intronic
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sequences distal from the intron/exon junctions). Mutations located in other
genes can also be responsible for the frequent occurrence of breast (and
ovarian) cancer in a Íraction of the families. HoWeVer such genes, with a clear
dominant cancer predisposing phenotype comparable to what is observed
with BRCAI or BRCA2 mutations, have not been reported yet.
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